MEIP - MEI Pharma, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

MEI Pharma, Inc.

3611 Valley Centre Drive
Suite 500
San Diego, CA 92130
United States
858-369-7100
http://www.meipharma.com

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees32

Key Executives

NameTitlePayExercisedYear Born
Dr. Daniel P. GoldCEO, Pres & Director903.57kN/A1954
Mr. Brian G. Drazba CPASec. & CFO483kN/A1961
Mr. David M. Urso Esq., J.D.COO, Sr. VP of Corp. Devel. & Gen. Counsel538.2kN/A1964
Dr. Robert D. Mass M.D.Chief Medical Officer253.01kN/A1954
Mr. David A. WalseyVP of IR & Corp. CommunicationsN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

MEI Pharma, Inc., a pharmaceutical company, focuses on the clinical development of novel therapies for the treatment of cancer. The company's clinical drug candidate includes Pracinostat, an oral available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia or follicular lymphoma; ME-344, an isoflavone-derived mitochondrial inhibitor for the treatment of HER2-negative breast cancer; and Voruciclib, an oral cyclin-dependent kinase inhibitor. The company has a license, development, and commercialization agreement with Helsinn Healthcare SA for the development, manufacture, and commercialization of Pracinostat; and license agreement with Presage Biosciences, Inc. to develop, manufacture, and commercialize Voruciclib, a clinical-stage, oral, and selective cyclin-dependent kinase inhibitor; and related compounds. It also has a clinical collaboration agreement with BeiGene, Ltd. to evaluate the safety and efficacy of ME-401 in combination with BeiGene's zanubrutinib, an investigational BTK inhibitor for the treatment of patients with B-cell malignancies. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California.

Corporate Governance

MEI Pharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.